-
TGA approves new Comirnaty vax
Wednesday | Dec 10 2025PFIZER Australia and BioNTech have welcomed the Australian Register of Therapeutic Goods (ARTG) registration of the companies’ LP.8.1-adapted COVID-19 vaccine – Comirnaty LP.8.1 – for use in individuals six months and older.
-
Intern of the year nominations open
Wednesday | Dec 10 2025NOMINATIONS are now open for the 2025 MIMS / College Intern of the Year (IOTY) Award, the Australasian College of Pharmacy has announced.
-
Grants to connect cancer services
Wednesday | Dec 10 2025THE Australian Government has announced $1 million in funding for projects that build stronger networks between cancer services in outer metropolitan, regional, rural, and remote communities, and larger metropolitan centres.
-
Clinically tested care for cracked heels
Wednesday | Dec 10 2025DERMAL Therapy Heel Balm Platinum offers pharmacists a clinically tested solution for customers with extremely dry, cracked heels.
-
Mag-Sup powder – a better way to absorb magnesium
Wednesday | Dec 10 2025MAG-SUP powder is a high absorption magnesium supplement for use in magnesium deficiencies. It contains magnesium aspartate which has increased bioavailability compared to other forms of magnesium. Magnesium aspartate has better oral absorption than magnesium citrate, magnesium glycinate, magnesium chloride and magnesium oxide.
-
Med safety standard update
Wednesday | Dec 10 2025ADVANCED Pharmacy Australia (AdPha) has released a newly updated pharmacy practice standard for medication safety, now available through early view in the Journal of Pharmacy Practice and Research.
-
Full scope to free up ED
Wednesday | Dec 10 2025UNLOCKING full scope of pharmacist practice could divert thousands of patients from NSW emergency departments and hospital beds, reducing wait times and freeing up resources for those who need them most, according to a new report from Deloitte Access Economics.
-
Arrotex launches hayfever drug
Wednesday | Dec 10 2025ARROTEX Pharmaceuticals has launched ARX-Fluticasone (fluticasone furoate) Nasal Spray, the first generic alternative brand of its kind available in Australia for the treatment of seasonal and perennial allergic rhinitis in adults and children aged two years and older.
-
TGA approves new Comirnaty vax
Wednesday | Dec 10 2025PFIZER Australia and BioNTech have welcomed the Australian Register of Therapeutic Goods (ARTG) registration of the companies’ LP.8.1-adapted COVID-19 vaccine – Comirnaty LP.8.1 – for use in individuals six months and older.
-
Intern of the year nominations open
Wednesday | Dec 10 2025NOMINATIONS are now open for the 2025 MIMS / College Intern of the Year (IOTY) Award, the Australasian College of Pharmacy has announced.
PARTNER SITES
to top